Drug interactions
Human papillomavirus vaccine nonavalent + Ocrelizumab
Severity: Moderate
Human papillomavirus vaccine nonavalent and Ocrelizumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ocrelizumab-induced B-cell depletion may blunt antibody responses to the inactivated HPV vaccine, leaving patients less protected. The vaccine is not unsafe in this setting.
What this interaction means in plain words
Human papillomavirus vaccine nonavalent and Ocrelizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Depletion of CD20-positive B cells impairs humoral immune responses to vaccine antigens.
What to do
Complete HPV vaccination at least 2 weeks before starting ocrelizumab where feasible. If given during therapy, accept that the response may be reduced and consider the timing relative to B-cell recovery.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Human papillomavirus vaccine nonavalent and Ocrelizumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ocrelizumab
- Adenovirus types 4 and 7 live + Ocrelizumab Contraindicated
- Influenza virus vaccine quadrivalent intranasal + Ocrelizumab Contraindicated
- Measles mumps and rubella vaccine live + Ocrelizumab Contraindicated
- Measles mumps rubella and varicella vaccine live + Ocrelizumab Contraindicated
- Measles vaccine + Ocrelizumab Contraindicated
- Anti-thymocyte + Ocrelizumab Major
Frequently asked questions
Can I take Human papillomavirus vaccine nonavalent with Ocrelizumab?
MediHelp rates the interaction as moderate. Human papillomavirus vaccine nonavalent and Ocrelizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ocrelizumab-induced B-cell depletion may blunt antibody responses to the inactivated HPV vaccine, leaving patients less protected. The vaccine is not unsafe in this setting.
How serious is the interaction between Human papillomavirus vaccine nonavalent and Ocrelizumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Complete HPV vaccination at least 2 weeks before starting ocrelizumab where feasible. If given during therapy, accept that the response may be reduced and consider the timing relative to B-cell recovery.
What other medicines interact with Ocrelizumab?
MediHelp also lists interactions of Ocrelizumab with, for example, Adenovirus types 4 and 7 live, Influenza virus vaccine quadrivalent intranasal, Measles mumps and rubella vaccine live. The full list is on the Ocrelizumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
